McKesson and Cardinal Health Extend CVS Drug Supply Deals Through 2032
BofA kept Buy ratings, calling the news a clearing event.
/ 10 items
#CVS↓
CVS Beats Q2 Expectations and Raises 2026 Guidance, But Shares Drop on Soft 2027 Outlook
CVS Health reports strong Q2 results with $2.58 adjusted EPS and raises 2026 guidance, but shares fall on a muted 2027 outlook and cautious cost warnings.
CVS Health Raises 2026 Guidance After Strong Q1 Beat and Better Cost Controls
CVS had strong Q1: revenue $100.4B, earnings beat expectations, raised outlook, cash flow up. Stock rose.
Insurer Stocks Soar After CMS Finalizes 2027 Medicare Payments
CMS boosts 2027 Medicare payments 2.5%, giving insurers $13B+, keeping plans stable and seniors’ benefits solid. Stocks jump.
CVS Health Misses 2026 Profit Forecast, Shares Drop
CVS Health falls short of Wall Street's 2026 profit expectations despite beating Q4 estimates. Stock drops 3% as company maintains cautious outlook amid healthcare industry challenges.
Trump Administration Proposes Near-Flat Medicare Advantage Rates, Disappointing Insurers
Trump's CMS proposes minimal 0.09% Medicare payment increase for 2027, far below Wall Street's 4-6% expectations, while eliminating controversial billing practices.